Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Statements of Stockholder's Equity

Statements of Stockholder's Equity - USD ($)	Total	Common Classes A Member	Common Classes B Member	Series One Preferred Member	Sereies One A Preferred Member	Series One A Warrants Member	Series One B Preferred Member	Series One C Preferred Member	Series One D Preferred Member	Preferred Stock Member	Preferred Stock Warrants Member	Common Stock	Additional Paid-In Capital [Mmber]	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2020		508,777	1,767,477	6,906,244	5,018,750	1,419,228	6,500,000	46,553,188
Balance, amount at Dec. 31, 2020	$ (3,177,939)	$ 10,430	$ 2,342,853	$ 6,833,877	$ 4,380,081	$ 723,431	$ 4,119,595	$ 6,491,592						$ (28,079,798)
Series 1d Preferred Units issued, shares									6,065,989
Series 1d Preferred Units issued, amount	5,034,801								$ 5,034,801
Class B Common Units forfeited, shares			(22,494)
Conversion of Common Units to Common Stock, shares		(508,777)	(1,744,983)									1,911,009
Conversion of Common Units to Common Stock, amount	0	$ (10,430)	$ (2,342,853)									$ 191	$ 2,353,092
Conversion of Preferred Units to Preferred Stock, shares				(6,906,244)	(5,018,750)		(6,500,000)	(46,553,188)	(6,065,989)	71,044,171
Conversion of Preferred Units to Preferred Stock, amount	0			$ (6,833,877)	$ (4,380,081)		$ (4,119,595)	$ (6,491,592)	$ (5,034,801)	$ 7,104			26,852,842
Conversion of Warrant Units to Preferred Stock, shares						(1,419,228)					1,419,228
Conversion of Warrant Units to Preferred Stock, amount	0					$ (723,431)					$ 142		723,289
Redemption of Series 1c preferred shares, shares										(5,221,156)
Redemption of Series 1c preferred shares, amount	(1,000,000)									$ (522)			(999,478)
Conversion of Preferred Stock to Common Stock, shares										(65,823,015)		3,813,973
Conversion of Preferred Stock to Common Stock, amount	0									$ (6,582)		$ 381	6,200
Conversion of Preferred Stock Warrants to Common Stock Warrants, shares											(1,419,228)
Conversion of Preferred Stock Warrants to Common Stock Warrants, amount	(142)												142
Conversion of Convertible Debt to Common Stock, shares												32,219
Conversion of Convertible Debt to Common Stock, amount	180,434											$ 3	180,430
Issuance of Common Stock and warrants, net issuance costs, shares												2,571,428
Issuance of Common Stock and warrants, net issuance costs, amount	15,385,563											$ 257	15,385,306
Stock-based compensation													1,586,722
Net loss	(7,902,477)
Balance, shares at Dec. 31, 2021												8,328,629
Balance, amount at Dec. 31, 2021	10,107,104											$ 833	46,088,546	(35,982,275)
Issuance of Common Stock and warrants, net issuance costs, shares												898,585
Stock-based compensation	1,082,136
Net loss	(9,610,913)												1,082,136	(9,610,913)
Issuance of common stock and warrants, net of issuance costs, amount	4,276,365											$ 90	4,276,275
Issuance of common stock upon exercise of pre-funded warrants, shares												2,875,000
Issuance of common stock upon exercise of pre-funded warrants, amount	287											$ 287
Issuance of restricted stock unit awards, amount	166,875												166,875
Issuance of common stock upon conversion of restricted stock units, shares												219,634
Issuance of common stock upon conversion of restricted stock units, amount												$ 22	(22)
Balance, shares at Dec. 31, 2022												12,321,848
Balance, amount at Dec. 31, 2022	$ 6,021,854	$ 0	$ 0					$ 0	$ 0	$ 0	$ 0	$ 1,232	$ 51,613,810	$ (45,593,188)